Canakinumab for treating systemic juvenile idiopathic arthritis (terminated appraisal)

Juvenile idiopathic arthritis (systemic) - canakinumab (terminated appraisal): review decision April 2015 information

Juvenile idiopathic arthritis (systemic) - canakinumab (terminated appraisal): appendix A - GE decision paper - March 2015

Juvenile idiopathic arthritis (systemic) - canakinumab (terminated appraisal): appendix A - GE decision paper - March 2015 (PDF 107 KB)

Juvenile idiopathic arthritis (systemic) - canakinumab (terminated appraisal): review proposal information

Juvenile idiopathic arthritis (systemic) - canakinumab (terminated appraisal): appendix B - GE Proposal Paper January 2015

Juvenile idiopathic arthritis (systemic) - canakinumab (terminated appraisal): appendix B - GE Proposal Paper January 2015 (PDF 239 KB)

Juvenile idiopathic arthritis (systemic) - canakinumab (terminated appraisal): appendix A - matrix of stakeholders

Juvenile idiopathic arthritis (systemic) - canakinumab: equality impact assessment - scoping

Systemic Juvenile idiopathic arthritis - canakinumab: final scope

Systemic Juvenile idiopathic arthritis - canakinumab: final matrix

Systemic Juvenile idiopathic arthritis - canakinumab: NICE's response to consultee and commentator comments on the draft scope and provisional matrix 

Systemic Juvenile idiopathic arthritis - canakinumab: provisional matrix (post-referral)

Systemic Juvenile idiopathic arthritis - canakinumab: draft scope (post-referral)

Arthritis (juvenile idiopathic, systemic) - canakinumab: Appendix C - provisional matrix (pre-referral) - October 2011

Arthritis (juvenile idiopathic, systemic) - canakinumab: Appendix B - draft scope for consultation (pre-referral) - October 2011